Bi-yun Wang
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Effectiveness, safety, and biomarker analysis of sacituzumab govitecan in Chinese metastatic breast cancer: a multicenter real-world study.
Journal: Therapeutic advances in medical oncology
Published: November 25, 2025
Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
Journal: Cancer communications (London, England)
Published: December 19, 2022
Maintenance chemotherapy is effective in patients with metastatic triple negative breast cancer after first-line platinum-based chemotherapy.
Journal: Annals of palliative medicine
Published: March 07, 2020
Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study.
Journal: Breast cancer research and treatment
Published: November 28, 2017
Erratum to: Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer.
Journal: Journal of experimental & clinical cancer research : CR
Published: September 01, 2015
Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer.
Journal: Journal of experimental & clinical cancer research : CR
Published: June 22, 2015
The human chemokine receptor CCRL2 suppresses chemotaxis and invasion by blocking CCL2-induced phosphorylation of p38 MAPK in human breast cancer cells.
Journal: Medical oncology (Northwood, London, England)
Published: June 20, 2015
Gossypium barbadense genome sequence provides insight into the evolution of extra-long staple fiber and specialized metabolites.
Journal: Scientific reports
Published: April 07, 2015
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
Journal: The Lancet. Oncology
Published: March 22, 2015
The SUVmax for (18)F-FDG correlates with molecular subtype and survival of previously untreated metastatic breast cancer.
Journal: Clinical nuclear medicine
Published: February 23, 2013
The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer.
Journal: BMC cancer
Published: October 30, 2012
Last Updated: 09/26/2026